

Glenmark receives 2 ANDA approvals from the FDA

21 January 2016 | News | By BioSpectrum Bureau

Glenmark receives 2 ANDA approvals from the FDA



Glenmark Pharmaceuticals USA (Glenmark) has been granted final approval by the United States Food and Drug Administration (US FDA) for Potassium Chloride Extended-Release Capsules USP, 10 mEq. The drug is therapeutic equivalent to the reference listed drug product, Potassium Chloride Extended-Release Capsules USP, 10 mEq, of Actavis Laboratories.

According to IMS Health sales data for the 12 month period ending November 2015, the Potassium Chloride Extended-Release Capsules, 10 mEq Market achieved annual sales of approximately \$74.1 million.

Glenmark has also been granted final approval by US FDA for Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg, the generic version of Loestrin 21 1/20 Tablets of Warner Chilcott Company.

According to IMS Health sales data for the 12 month period ending November 2015, the Loestrin 21 1/20 Tablets market1 achieved annual sales of approximately \$56.8 million.